Optimizing the Beneficial Health Effects of Exercise for Diabetes: Focus on the Liver!

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

81 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-03-31

Study Completion Date

2015-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Due to the western lifestyle, correlated with a high calorie intake and low physical activity, obesity is becoming a major health problem. All over the world obesity reaches epidemic proportions. Obesity is closely linked to type 2 diabetes, a multi-factorial disease that increases the presence of multiple health problems. Until now, exercise and dietary intervention seem to be the single most effective interventions to treat obesity and type 2 diabetes mellitus. In obesity and type 2 diabetes, not only fat accumulation in adipose tissue, but also fat accumulation in the peripheral tissues occurs. Fat accumulation in peripheral tissues has been associated with insulin resistance. Exercise seems to have a positive effect on the accumulation of fat in the peripheral tissue and on the insulin sensitivity in type 2 diabetic patients.

In this study we want to investigate if a prolonged exercise training program can lower the intrahepatic lipid content and can improve the metabolism of the liver in type 2 diabetic patients and patients with non-alcoholic fatty liver disease, and to examine if this leads to improvements in metabolic risk markers. To this end, we will include investigation of the effect of exercise on adipose tissue (inflammatory markers and adipocyte size) and skeletal muscle (ex vivo lipid metabolism) to incorporate the effect of exercise on liver, muscle and adipose tissue and to clarify the crosstalk between these tissues in the pathophysiology of type 2 diabetes.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Effect of Exercise on Hepatic Glucose Metabolism

NCT01783275

Obesity Type 2 Diabetes

COMPLETED NA

Exercise and Glycemic Control in Type 2 Diabetes

NCT00945165

Diabetes Mellitus, Type 2 Hyperglycemia

COMPLETED NA

Restoring 24-hour Substrate Rhythmicity to Improve Glycemic Control by Timing of Lifestyle Factors

NCT05123963

Prediabetic State

RECRUITING NA

The Effect of Exercise on the Brain in Type 2 Diabetes

NCT06734546

Type 2 Diabetes

ENROLLING_BY_INVITATION NA

Exercise Training and Type 2 Diabetes

NCT06478173

Type2diabetes

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetes Mellitus, Type 2 Non-alcoholic Fatty Liver Disease Obesity

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Healthy control

This group will exist of healthy obese that are matched for BMI and age with the type 2 diabetes group and non-alcoholic fatty liver disease group.

Group Type EXPERIMENTAL

Exercise intervention

Intervention Type BEHAVIORAL

Subjects will be training for 12 week, 3 times a week. Two times a week they will perform a 30 minutes bicycle training. Once a week they will perform a 30 minutes resistance training.

Non-alcoholic fatty liver disease

This group will exist of people that suffer from non-alcoholic fatty liver disease. They will be matched for BMI and age according to the Type 2 diabetes group

Group Type EXPERIMENTAL

Exercise intervention

Intervention Type BEHAVIORAL

Subjects will be training for 12 week, 3 times a week. Two times a week they will perform a 30 minutes bicycle training. Once a week they will perform a 30 minutes resistance training.

Type 2 diabetes patients

This group will exist of patients that suffer from type 2 diabetes

Group Type EXPERIMENTAL

Exercise intervention

Intervention Type BEHAVIORAL

Subjects will be training for 12 week, 3 times a week. Two times a week they will perform a 30 minutes bicycle training. Once a week they will perform a 30 minutes resistance training.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Exercise intervention

Subjects will be training for 12 week, 3 times a week. Two times a week they will perform a 30 minutes bicycle training. Once a week they will perform a 30 minutes resistance training.

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. All subjects:

* Male sex
* Age 40-70 years
* BMI 27-35 kg/m2
* Stable dietary habits
* Sedentary: No participation in any kind of sports for at least 2 years.
2. For diabetic patients only:

* Must be on sulphonylurea or metformin therapy for at least 6 months with constant dose for at least 2 months, or on a dietary treatment for at least 6 months
* Well-controlled diabetes: fasting plasma glucose concentration ≥ 7.0 mmol/l and \< 10.0 mmol/l at the time of screening.
3. For subjects with non-alcoholic fatty liver disease:

* Liver fat content ≥ 5,56%, based on the formula of Kotronen et al. and confirmed with MRS.
* Fasting plasma glucose concentration must be \< 7.0 mmol/l
4. For control subjects:

* Liver fat content \< 5,56%, based on the formula of Kotronen et al. and confirmed with MRS.
* Normoglycemic according to the WHO criteria (OGTT)

Exclusion Criteria

1. All subjects:

* Female sex
* Unstable body weight (weight gain or loss \> 3 kg in the past three months)
* Participation in an intensive weight-loss program or in vigorous exercise program during the last year before the start of the study.
* Active cardiovascular disease. (This will be determined by questionnaires and by screening on medication. Furthermore, all subjects will undergo a physical examination by a medical doctor).
* Chronic renal dysfunction (creatinine \> 2 increased (normal values: 64-104 µmol/l))
* Use of Thiazolidines (glitazone/rosiglitazone/pioglitazone/troglitazone)
* Systolic blood pressure \> 160 mmHg or diastolic blood pressure \> 100 mmHg
* Haemoglobin \< 7.5 mmol/l (anaemia)
* Blood donor
* Use of medication known to interfere with glucose homeostasis (i.e. corticosteroids), except for diabetic patients.
* Use of anti-thrombotic medication
* Claustrophobia and contra-indications for MRI
* Abuse of alcohol(\> 3 units (1unit = 10 gram ethanol) per day)
* Abuse of drugs
* Participation in another biomedical study within 1 month before the first screening visit
2. For diabetics:

* Severe diabetes which requires application of insulin or patients with diabetes-related complications
3. For controls:

* Liver disease or liver dysfunction (ALAT \> 2.5 x increased)

Minimum Eligible Age

40 Years

Maximum Eligible Age

70 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes